• Legal Disclaimer

     

    All use of the Rosacea Research & Development Institute (RRDi or irosacea.org) Web site is subject to the terms and conditions set forth below. When referring to the Rosacea Research & Development Institute (RRDi or irosacea.org) in this legal discaimer includes the following domains:

    irosacea.org
    rosaceans.com
    rrdinstitute.org
    rosacea-control.com
    rosacea-research-and-development-institute.org

    legal_disclaimer.png

    Any use of such Web pages constitutes the user's agreement to abide by the following terms and conditions.

    The Rosacea Research & Development Institute [RRDi] is a non profit corporation in the state of Hawaii, USA recognized June 7, 2004 by USA Internal Revenue Service as a 501 (c) (3) non profit tax exempt organization.

    All medical information on this Web site has been reviewed for accuracy. However, the information posted here by the Rosacea Research & Development Institute or any third party should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The Institute does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case.

    Links to other Web sites found on irosacea.org are provided as a service to our users. Such linkage does not constitute endorsement of the site by the Rosacea Research & Development Institute, and the Institute is not responsible for the content of external web sites. Links to commercial rosacea web sites are prohibited at this time.

    The Rosacea Research & Development Institute Web pages are designed for educational purposes only. This information is not intended to substitute for informed medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified health care provider. The Rosacea Research & Development Institute does not endorse or attest to the validity or accuracy of any treatments or medications discussed herein. Before acting on any information contained on the Web pages, you agree that you will consult your health care provider to determine whether the information you are relying on is appropriate for your medical condition.

    All information provided by the Rosacea Research & Development Institute is owned by or licensed to the Rosacea Research & Development Institute. The Rosacea Research & Development Institute retains all proprietary rights to the information contained on the pages. Except for making one hard copy print of the information or downloading the material for a one-time use, information on the pages may not be reproduced, transmitted, distributed, or displayed, without the express consent of the Rosacea Research & Development Institute.

    THIS WEB SITE IS PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. THIS WEB SITE COULD INCLUDE TECHNICAL INACCURACIES OR TYPOGRAPHICAL ERRORS. CHANGES ARE PERIODICALLY ADDED TO THE INFORMATION HEREIN; THESE CHANGES WILL BE INCORPORATED IN NEW EDITIONS OF THE WEB SITE. THE ROSACEA RESEARCH & DEVELOPMENT INSTITUTE MAY MAKE IMPROVEMENTS AND/OR CHANGES TO THE PROGRAM(S) DESCRIBED IN THIS WEB SITE AT ANY TIME

    NOTICE AND TAKEDOWN PROCEDURES; COPYRIGHT AGENT

    The RRDi does not knowlingly use any material (images or text) that is copyrighted by others. If you believe any materials accessible on or from this web site infringe your copyright, you may request removal of those materials (or access thereto) from this web site by The RRDi copyright agent (identified below) and providing the following information:
    Identification of the copyrighted work that you believe to be infringed. Please describe the work, and where possible include a copy or the location (e.g., URL) of an authorized version of the work. Identification of the material that you believe to be infringing and its location. Please describe the material, and provide us with its URL or any other pertinent information that will allow us to locate the material. Your name, address, telephone number and (if available) e-mail address.
    A statement that you have a good faith belief that the complained of use of the materials is not authorized by the copyright owner, its agent, or the law.
    A statement that the information that you have supplied is accurate, and indicating that "under penalty of perjury," you are the copyright owner or are authorized to act on the copyright owners behalf.

    A signature or the electronic equivalent from the copyright holder or authorized representative.

    The irosacea.org agent for copyright issues relating to this web site is as follows:

    Copyright Agent
    RRDi
    PO Box 235611
    Honolulu, Hawaii, 96823

    In an effort to protect the rights of copyright owners, the irosacea.org maintains a policy for the termination, in appropriate circumstances, of subscribers and account holders of this web site who are repeat infringers.

    International Disclaimer

    This Web site can be accessed from other countries around the world and may contain references to rosacea products, services, treatments or programs that have not been announced in your country. These references do not imply that irosacea.org intends to announce such products, services or programs in your country.

    Governing Law and Jurisdiction

    This web site (excluding linked sites) is controlled by irosacea.org from its office within the state of Hawaii, United States of America. By accessing this Web site, you and irosacea.org agree that all matters relating to your access to, or use of, this Web site shall be governed by the statutes and laws of the state of Hawaii, without regard to the conflicts of laws principles thereof. You and irosacea.org also agree and hereby submit to the exclusive personal jurisdiction and venue of the Superior Court of the District of Honolulu, Honolulu County and the United States District Court for the District of Hawaii with respect to such matters. irosacea.org makes no representation that materials on this Web site are appropriate or available for use in other locations, and accessing them from territories where their contents are illegal is prohibited. Those who choose to access this site from other locations do so on their own initiative and are responsible for compliance with local laws.

    Privacy Policy

    Our Privacy Policy is the commitment to respect the privacy of the information entrusted to our institute with your personal information by not giving your personal information to others or using it inappropriately. If you have any questions or concerns regarding our privacy policy please direct them to privacy@irosacea.org

    You may also send a letter to:

    Rosacea Research & Development Institute, PO Box 235611, Honolulu, Hawaii, 96823

    irosacea.org does not sell, exchange, or release your personal information (name, e-mail address, mailing address, credit card data, etc.) without your consent to any third parties.

    Information gathered through the use of cookies is not related to any personally identifiable details.

    What information does irosacea.org collect from our users and how do we collect it?

    irosacea.org only contacts individuals who specifically request that we do so. irosacea.org collects personally identifying information from our users during (1) online registration, (2) online public surveys, (3) online purchasing, and (4) messages posted to our public forum board and the private forum. Generally, this information includes name, e-mail address, postal address, and answers to public survey questions. This information is used for internal purposes and helps us determine how to continually improve our site and the institute. Names and email addresses may be posted in public forums and public databases by individual members who post such information on their own. The RRDi is not responsible if a member posts their own real name, address, phone number, or email address. If a member later regrets posting this information the member can report where the post is and have it removed upon request. If you do not want your name listed in any of the public surveys or databases you should use a bogus name or alias (nickname) since the institute is not responsible if you use your real name or email address in a public survey or database. However, the institute will not publicly display any of the members names, email addresses or postal addresses. Each member is responsible for his or her own privacy when using any of the institute's web site when posting.

    Members who donate to the RRDi are named in public financial records unless the donor specifically instructs us that the donation is anonymous.

    Corporate Members Forum Guidelines and Privacy Policy

    The corporate members only private forum is provided as a free service of the RRDi. Volunteers of the insitute spent hours working on this forum. The institute will not release any names, mailing addresses or email addresses of who is using this private forum to any third parties without your consent. Privacy is important to the RRDi and you can rest assured your contact information is safe with us and we will not disclose your contact info to anyone without your permission or only if we are required by law to disclose your contact info. The privacy policy also includes the Member Chat, Blog and Gallery areas of our site. The Guidelines policy is enforced and binding on all members and guests.

    Chat, Blog and Gallery

    The Chat, Blog and Gallery, if available, are provided as a free service by the RRDi to its members only and you are responsible for your own privacy with regard to this service if you engage with another member and disclose your private information in the Chat, post a Blog, or post photos in the Gallery. The RRDi cannot be held responsible for your privacy if you use the Chat, Blog or Gallery and our privacy policy, legal disclaimer, rules, and official documents are still binding if you violate this policy. At this time the chat is limited to five members at a time. We warn you to not disclose your private information or post inappropriate content in the Chat, Blog or Gallery.

    The institute will not release any names or email addresses of who is using the Chat, Blog or Gallery service without your consent.

    Cookies

    What are cookies and how do we use them?

    Cookies help track a person''s session while online. They are used on our site to gather basic tracking information. Cookies are not related to any personally identifiable information and are not used to retrieve information from your computer that was not originally sent in a cookie.

    Many browsers are set to accept cookies. You may prefer to set your browser to refuse cookies. It is possible, however, that some areas of the site will not function properly if you do so. This is especially likely when trying to order a publication.

    Third-Party Advertising

    Advertisements are not currently allowed on this site. If advertisements are allowed then information about your visits to this site, such as the number of times you have viewed an ad (but not your name, address, or other personal information), is used to serve ads to you. In the course of serving advertisements to this site, third-party advertisers may place or recognize unique cookies on your browser. Links to third-party advertising, or commercial web sites are prohibited.

    Amazon Affiliate

    The RRDi has joined Amazon Affiliates and links to items at amazon.com may be placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.

    Demodex Solutions Affiliate

    The RRDi has joined the Demodex Solutions affiliate program and links to this program are placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.

    Disclaimer

    This policy may be changed at any time at Rosacea Research & Development Institute's discretion.

    Copyright

    © Rosacea Research & Development Institute. All rights reserved. Reproduction, re-transmission or reprinting of the contents of this Web site, in part or in its entirety, is expressly prohibited without prior written permission from the Rosacea Research & Development Institute.



  • Member Statistics

    • Total Members
      1,037
    • Most Online
      325

    Newest Member
    densergar
    Joined
  • Posts

    • You may be able to save some money using the Mission Pharmacal Savings Card program for their product line. 
    • The following nine products are recommended by Cosmopolitan:  Aveeno Ultra-Calming Nourishing Night Cream

      La Roche-Posay Rosaliac AR Intense

      Cetaphil Redness Relieving Daily Facial Moisturizer

      First Aid Beauty Anti Redness Serum

      Skinceuticals Redness Neutralizer

      Elemis Daily Redness Solution

      Eucerin Sensitive Skin Redness Relief Soothing Night Creme Rhofade

      IT COSMETICS Your Skin But Better CC Cream Light
        9 Products You're Not Using to Calm Your Rosacea but Should, by CARLY CARDELLINO, Cosmopolitan
    • After a couple of pool visits, I noticed a rash forming on my arms and blotchy, red patches on my face. Like a responsible adult woman, I decided to see my family doctor who told me that the condition of my skin was “concerning” and “may have been caused by chlorine.” The doctor diagnosed it as “probably rosacea” and prescribed me an antibiotic compound cream which I have to slather on my face three times a day. Letter: The new pool gave me dry skin, a rash and probably rosacea, By Anita Rudakov. The Ubyssy
    • Related Articles TRPV4 Moves toward Center-Fold in Rosacea Pathogenesis. J Invest Dermatol. 2017 Apr;137(4):801-804 Authors: Chen Y, Moore CD, Zhang JY, Hall RP, MacLeod AS, Liedtke W Abstract
      Mascarenhas et al. report that TRPV4 expression is upregulated in mast cells in response to the proteolytic cathelicidin fragment LL37 in a murine rosacea model and that TRPV4 loss of function attenuates mast cell degranulation. These findings render TRPV4 a translational-medical target in rosacea. However, signaling mechanisms causing increased expression of TRPV4 await elucidation. Moreover, we ask whether TRPV4-mediated Ca(++)-influx evokes mast cell degranulation.
      PMID: 28340683 [PubMed - in process] {url} = URL to article
    • Related Articles Giant Rhinophyma: A Rare Case of Total Nasal Obstruction and Restitutio Ad Integrum. Aesthetic Plast Surg. 2017 Mar 24;: Authors: Wolter A, Scholz T, Liebau J Abstract
      Rhinophyma is considered the end stage in the development of rosacea, accompanied by hypertrophy of the sebaceous glands, which causes an enlargement of the nose. It is an uncommon condition that often results in both functional and cosmetic impairment. A large variety of surgical and nonsurgical treatments have been published to treat it. Closure is usually obtained by wound granulating in by secondary intention, skin grafting or local flaps. Rarely these lesions can attain a giant size and pose a challenge in surgical treatment. We present a 63-year-old male with the necessity for tracheostomy at the ICU due to total nasal obstruction and recurrent episodes of pneumonia caused by a huge giant rhinophyma, which had undergone extreme growth in the last five years. The tumor was removed under general anesthesia by decortication with an electrosurgical wire loop to recreate the aesthetic units of the nose preserving the alar cartilage as well as the pilosebaceous appendages. The wounds healed in by secondary intention with a very pleasant cosmetic and improved functional result. The relevant literature is discussed. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
      PMID: 28341953 [PubMed - as supplied by publisher] {url} = URL to article
    • Nu-Stock is a cream for animals, yet some at RF have reported using it, usually by mixing it with something, i.e., zinc cream, etc., and report it works. The list is a daunting challenge to go through. However one typical example is decade plus's formula:  50%-Boudreaux's Butt Cream 40% Zinc Oxide
      50%-Nu-Stock 72% Sufur
      2 drops TTO In post no. 5, decade plus writes, "I have been forced to discontinue this treatment," and we never hear from this poster again.  There are other formulas:  flurb's post no 15 who says to "Apply even mixture of Shea Butter Moisturizer, Nu-Stock and add 1-2 drops of tea tree oil." Suggest you search for yourself. 
    • Rosacea treatments pay attention to 3 key categories: patient education, skin care, and pharmacologic interventions. 
      Photoprotection and moisturizers are important because rosacea skin has increased transepidermal water loss. Patients should avoid triggers like wind, hot and cold temperatures, exercise, spicy foods, alcohol, hot drinks, and physical or psychological stress. Treatment that minimizes symptoms is possible, but it is more important that you learn how to live with it. Spring can be challenging for Rosacea sufferers, by Fiona Heavey, Leitrim Observer,
    • Rosacea: Causes and Treatment [Interview] [Transcript], Estee Williams, M.D., Health Professional Radio 
    • Related Articles Skin disorders in Parkinson's disease: potential biomarkers and risk factors. Clin Cosmet Investig Dermatol. 2017;10:87-92 Authors: Ravn AH, Thyssen JP, Egeberg A Abstract
      Parkinson's disease (PD) is one of the most common neurodegenerative disorders, characterized by a symptom triad comprising resting tremor, rigidity, and akinesia. In addition, non-motor symptoms of PD are well recognized and often precede the overt motor manifestations. Cutaneous manifestations as markers of PD have long been discussed, and cumulative evidence shows an increased prevalence of certain dermatological disorders in PD. Seborrheic dermatitis is considered to occur as a premotor feature of PD referable to dysregulation of the autonomic nervous system. Also, an increased risk of melanoma has been observed in PD. Light hair color is a known risk factor for melanoma, and interestingly the risk of PD is found to be significantly higher in individuals with light hair color and particularly with red hair. Furthermore, several studies have reported a high prevalence of PD in patients with bullous pemphigoid. Moreover, a 2-fold increase in risk of new-onset PD has been observed in patients with rosacea. Besides the association between PD and various dermatological disorders, the skin may be useful in the diagnosis of PD. Early PD pathology is found not only in the brain but also in extra-neuronal tissues. Thus, the protein α-synuclein, which is genetically associated with PD, is present not only in the CNS but also in the skin. Hence, higher values of α-synuclein have been observed in the skin of patients with PD. Furthermore, an increased risk of PD has been found in the Cys/Cys genotype, which is associated with red hair color. In this review, we summarize the current evidence of the association between PD and dermatological disorders, the cutaneous adverse effects of neurological medications, and describe the potential of skin protein expression and biomarkers in identification of risk and diagnosis of PD.
      PMID: 28331352 [PubMed - in process] {url} = URL to article
    • For quite some time one theory on rosacea is that sufferers have a nutritional deficiency. For more info. 
    • IPL Kills Mites "At a recent conference he reported that IPL appears to kill mites around hair follicles and sebaceous glands, which could make it useful in treating rosacea." Dispelling the Mystery of Demodex
      Issue Number: Volume 15 - Issue 1 - January 2007
      By Neal Bhatia, M.D., and James Q. Del Rosso, D.O., F.A.O.C.D., Using Intense Pulsed Light
    • Related Articles Selection of experimental strawberry (Fragaria x ananassa) hybrids based on selection indices. Genet Mol Res. 2017 Mar 08;16(1): Authors: Vieira SD, de Souza DC, Martins IA, Ribeiro GH, Resende LV, Ferraz AK, Galvão AG, de Resende JT Abstract
      The strawberry (Fragaria x ananassa Dutch.), is the only vegetable belonging to the rosacea family. All strawberry species have now emerged from wild species and belong to the genus Fragaria, being that this genus presents more than 45 described species, and only 11 are considered natural species. Due to the octoploid nature of strawberry and its variability after hybridization, selecting one or more characters may result in unfavorable genotypes and even the exclusion of promising ones, because negative genetic correlations have been observed among them that cause inefficient selection. Therefore, the objective of this study was to verify the efficiency of selection indices in selecting experimental strawberry hybrids for in natura consumption and processing. Seven commercial cultivars and 103 hybrids were used, which were obtained from populations derived from their crossings. The experiment was conducted in augmented blocks, in which four agronomical traits (total mass, amount of commercial fruit, amount of noncommercial fruit, and average fruit mass) and seven physical-chemical traits (soluble solids, soluble solids:titratable acidity ratio, total sugars, total pectin, vigor, and internal and external coloration) were evaluated. For hybrid selection, the following indices were used: Mulamba and Mock (1978), Smith (1936), Hazel (1943), and genotype-ideotype, which selected 20% of the genotypes evaluated. The three indices selected about 9% of the hybrids. The selection of two experimental hybrids (89 and 495) and the use of selection indices resulted in larger estimates of selection gains. The Mulamba and Mock (1978), Smith (1936), and Hazel (1943) indices had the highest percentage of gains on selection, and are therefore recommended for the selection of strawberry clones.
      PMID: 28290613 [PubMed - in process] {url} = URL to article